Bergen, 21 February 2007:
NorDiag ASA Q4 2006

NorDiag’s sample preparation capabilities received significant acknowledgement
International clinical documentation of Genefec well under way
Strategic IPR agreements achieved

NorDiag ASA reported a slight increase in revenues to NOK 1.3 million in the fourth quarter from NOK 1.2 million in the previous quarter. This was due to a marginal volume increase and a relatively stable pricing environment. Revenues fell short of the fourth quarter 2005 (1.8), as the laboratory efficiency was not fully restored until the first quarter 2007. The revenues for the full year 2006 reached NOK 5.8 million, which was a marginal increase from 2005 (NOK 5.7 million).

As commented on in the Q3-report, the Company’s sales volumes were affected by sample preparation issues in the second half of 2006. Although there was a gradually improvement during Q4, the issue still had a negative impact on volumes. Laboratory efficiency is back to normal in Q1-2007.

Recently the Company reported outstanding results in DNA sample preparation in a Scottish screening study. The study underlines that NorDiag’s methodology clearly outperforms other commercially available methods in sample preparation. Development of a more robust sample preparation method is well under way.

During Q4 the Company has achieved important progress related to clinical documentation on its main diagnostic product, Genefec. Clinical documentation is vital for market expansion. In the German study, 95 per cent of the samples needed is received. The previous commented Scottish study is expected to be completed in Q2. Additionally, a major European journal has accepted a case report regarding Genefec which shows Genefec’s advantages compared with other diagnostic methods.

NorDiag continued to extend its strategic groundwork of intellectual property rights (IPR) during Q4. An IPR considered key to NorDiag’s development of a first-line colorectal cancer screening; Screenfec, was acquired with world-wide exclusive rights. Tests conducted in-house show performance on par with major international studies. Also, a license agreement with Wellcome Trust for B-raf marker was signed in the quarter. This will contribute to a new generation Genefec with enhanced qualities. The Company is also evaluating a complementary marker in a new lung cancer test.

Nordiag’s cash balance at the end of Q4-2006 is NOK 40,9 million. The operating loss for the Company was NOK 6.5 million in the fourth quarter, which was an improvement compared with the loss of NOK 7.5 million in the third quarter and roughly on par with the loss of NOK 6.4 million in the fourth quarter 2005. The operating loss increased to NOK 27.6 million in 2006, compared with a loss of NOK 13.2 million in 2005. The increased loss is primarily related to an increase in R&D costs. This reflects improvements and automation of the laboratory process for Genefec and acceleration of research related to the development of Screenfec.

For further information, please contact; CEO Christian Horn in NorDiag ASA, phone: +47 90 16 31 53

About NorDiag ASA:
NorDiag is a biotechnology company with focus on early detection of cancer. The company`s first products are Genefec and GeneOpsy, for genetic diagnostics of colorectal cancer. In addition the company has R&D programmes for new technology and products for lung- and pancreatic cancer. NorDiag is listed on the Oslo Stock Exchange with the ticker NORD. See www.nordiag.no